Cosmo Pharmaceuticals
Cosmo Pharmaceuticals has announced impressive topline results from its two pivotal Phase 3 trials evaluating clascoterone 5% topical solution for male androgenic alopecia (AGA). These data mark what may be the first major therapeutic breakthrough for male-pattern hair loss in over 30 years. What is Clascoterone? Clascoterone is a topical androgen receptor inhibitor designed to…
Things are really heating up in the hair loss treatment industry on the first day of Summer 2023. Let’s take a look at all pertinent information and happenings in the AGA clinical trial world below. Cosmo Pharma Lists Phase 3 Trial On ClinicalTrials.gov A trial which was once highly anticipated, then questioned if it would…